1.60
price up icon7.38%   0.11
after-market After Hours: 1.60
loading
Precigen Inc stock is traded at $1.60, with a volume of 3.31M. It is up +7.38% in the last 24 hours and up +25.98% over the past month. Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$1.49
Open:
$1.51
24h Volume:
3.31M
Relative Volume:
2.16
Market Cap:
$468.59M
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-4.1026
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
+17.65%
1M Performance:
+25.98%
6M Performance:
+18.52%
1Y Performance:
+11.89%
1-Day Range:
Value
$1.47
$1.62
1-Week Range:
Value
$1.25
$1.62
52-Week Range:
Value
$0.6513
$1.93

Precigen Inc Stock (PGEN) Company Profile

Name
Name
Precigen Inc
Name
Phone
301-556-9900
Name
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Name
Employee
202
Name
Twitter
@precigen
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PGEN's Discussions on Twitter

Compare PGEN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PGEN
Precigen Inc
1.60 468.59M 6.23M -95.90M -68.47M -0.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
481.16 123.91B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
722.07 78.94B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
657.97 39.98B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
278.25 35.89B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
119.94 28.75B 3.30B -501.07M 1.03B -2.1146

Precigen Inc Stock (PGEN) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-22-24 Downgrade JP Morgan Neutral → Underweight
May-23-23 Initiated JP Morgan Neutral
Nov-18-22 Initiated Cantor Fitzgerald Overweight
Feb-25-21 Initiated Stifel Buy
Feb-22-21 Initiated Wells Fargo Overweight
Feb-18-21 Initiated B. Riley Securities Buy
May-08-20 Initiated H.C. Wainwright Buy
View All

Precigen Inc Stock (PGEN) Latest News

pulisher
Feb 06, 2025

A Deep Dive into Precigen Inc (PGEN) Stock Performance - The InvestChronicle

Feb 06, 2025
pulisher
Feb 04, 2025

JP Morgan analysts downgrades an Underweight rating for Precigen Inc (PGEN) - Knox Daily

Feb 04, 2025
pulisher
Feb 04, 2025

Is Precigen Inc (PGEN) a good investment opportunity? - US Post News

Feb 04, 2025
pulisher
Jan 27, 2025

Precigen, Inc. (NASDAQ:PGEN) Shares Sold by JPMorgan Chase & Co. - MarketBeat

Jan 27, 2025
pulisher
Jan 27, 2025

JPMorgan Chase & Co. Decreases Stake in Precigen, Inc. (NASDAQ:PGEN) - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

FY2024 EPS Estimates for Precigen Lifted by HC Wainwright - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

HC Wainwright Has Weak Outlook for Precigen FY2026 Earnings - Defense World

Jan 26, 2025
pulisher
Jan 26, 2025

Precigen’s (PGEN) Buy Rating Reiterated at HC Wainwright - Defense World

Jan 26, 2025
pulisher
Jan 24, 2025

Investors Purchase High Volume of Call Options on Precigen (NASDAQ:PGEN) - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

LexAurum Advisors LLC Raises Stock Holdings in Precigen, Inc. (NASDAQ:PGEN) - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

FY2026 EPS Estimates for Precigen Decreased by HC Wainwright - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Precigen (NASDAQ:PGEN) Earns Buy Rating from HC Wainwright - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Precigen Sees Unusually Large Options Volume (NASDAQ:PGEN) - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Precigen's SWOT analysis: biotech firm's stock poised for growth with PRGN-2012 - MSN

Jan 23, 2025
pulisher
Jan 23, 2025

Knight-Swift Transportation Posts Upbeat Earnings, Joins TAL Education, LSI Industries, GE Aerospace And Other Big Stocks Moving Higher On Thursday - Benzinga

Jan 23, 2025
pulisher
Jan 23, 2025

Precigen (NASDAQ:PGEN) Given Buy Rating at HC Wainwright - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Precigen, Inc. (NASDAQ:PGEN) Stock Position Increased by Barclays PLC - Defense World

Jan 23, 2025
pulisher
Jan 23, 2025

Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $6.33 - Defense World

Jan 23, 2025
pulisher
Jan 20, 2025

Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 20, 2025
pulisher
Jan 19, 2025

Precigen, Inc. Regains Compliance with Nasdaq Listing Rules - Defense World

Jan 19, 2025
pulisher
Jan 18, 2025

Precigen shares rebound above Nasdaq minimum bid price - MSN

Jan 18, 2025
pulisher
Jan 16, 2025

Precigen shares rebound above Nasdaq minimum bid price By Investing.com - Investing.com Australia

Jan 16, 2025
pulisher
Jan 16, 2025

Should You Invest in Precigen (PGEN)? - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

Jane Street Group LLC Reduces Stake in Precigen, Inc. (NASDAQ:PGEN) - Defense World

Jan 16, 2025
pulisher
Jan 15, 2025

Precigen's SWOT analysis: gene therapy stock focuses on RRP treatment By Investing.com - Investing.com Australia

Jan 15, 2025
pulisher
Jan 14, 2025

Precigen's SWOT analysis: gene therapy stock focuses on RRP treatment - Investing.com India

Jan 14, 2025
pulisher
Jan 14, 2025

Precigen's (PGEN) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

Precigen to Present Plans for Realizing Commercial Vision for PR - GuruFocus.com

Jan 13, 2025
pulisher
Jan 13, 2025

Precigen Files BLA for Breakthrough RRP Treatment PRGN-2012, Targets 27,000 US Patients - StockTitan

Jan 13, 2025
pulisher
Jan 10, 2025

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference - StreetInsider.com

Jan 10, 2025
pulisher
Jan 09, 2025

Precigen CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 09, 2025
pulisher
Jan 08, 2025

Barclays PLC Acquires 124,141 Shares of Precigen, Inc. (NASDAQ:PGEN) - Defense World

Jan 08, 2025
pulisher
Jan 07, 2025

Precigen, Inc. (NASDAQ:PGEN) Shares Bought by Geode Capital Management LLC - Defense World

Jan 07, 2025
pulisher
Jan 05, 2025

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally? - MSN

Jan 05, 2025
pulisher
Jan 03, 2025

Investors Buy Large Volume of Precigen Call Options (NASDAQ:PGEN) - Defense World

Jan 03, 2025
pulisher
Jan 02, 2025

Traders Purchase High Volume of Precigen Call Options (NASDAQ:PGEN) - MarketBeat

Jan 02, 2025
pulisher
Jan 01, 2025

Exploring 3 Prominent High Growth Tech Stocks In The United States - Simply Wall St

Jan 01, 2025
pulisher
Jan 01, 2025

Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail Sentiment Surges Amid Stock Rally - MSN

Jan 01, 2025
pulisher
Jan 01, 2025

Precigen, Inc. (NASDAQ:PGEN) Shares Acquired by State Street Corp - Defense World

Jan 01, 2025
pulisher
Dec 31, 2024

Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail - Asianet Newsable

Dec 31, 2024
pulisher
Dec 31, 2024

Stifel Financial Corp Raises Stock Position in Precigen, Inc. (NASDAQ:PGEN) - Defense World

Dec 31, 2024

Precigen Inc Stock (PGEN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$80.78
price down icon 0.82%
$20.67
price down icon 0.53%
$353.75
price down icon 0.12%
$5.04
price down icon 2.14%
biotechnology ONC
$228.87
price up icon 0.53%
$119.94
price down icon 1.99%
Cap:     |  Volume (24h):